Contineum Therapeutics (CTNM) reported second-quarter 2026 financial results and affirmed key clinical development milestones for its small molecule therapies targeting inflammatory and fibrotic diseases.

The company reported a net loss of $15.2 million for the quarter ended June 30, 2026, compared with $16.0 million in the second quarter of 2025. Cash, cash equivalents and marketable securities totaled $236.6 million as of June 30, 2026, with planned operations funded through mid-2029.

• Research and development expenses were $12.7 million, down 10% from the second quarter of 2025.
• General and administrative expenses were $4.7 million, up 23% from the prior-year quarter.
• Net loss per share, basic and diluted, was $0.40 for the second quarter of 2026.
• PROPEL-IPF, the Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, has more than 55 sites online in eight countries.
• Johnson & Johnson completed enrollment of 107 adult participants in the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder.
• Contineum streamlined discovery programs and reduced part of its research workforce, including the departure of Chief Scientific Officer Daniel Lorrain.

$CTNM Insider Trading Activity

$CTNM insiders have traded $CTNM stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.

Here’s a breakdown of recent trading of $CTNM stock by insiders over the last 6 months:

• DANIEL S. LORRAIN (Chief Scientific Officer) has made 0 purchases and 15 sales selling 63,523 shares for an estimated $977,257.
• CARMINE N. STENGONE (CEO and President) has made 0 purchases and 5 sales selling 20,000 shares for an estimated $320,207.
• TIM WATKINS (CMO & Head of Development) has made 0 purchases and 2 sales selling 14,444 shares for an estimated $227,810.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$CTNM Hedge Fund Activity

We have seen 44 institutional investors add shares of $CTNM stock to their portfolio, and 29 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• RA CAPITAL MANAGEMENT, L.P. removed 883,699 shares (-40.5%) from their portfolio in Q1 2026, for an estimated $11,541,108
• COMMODORE CAPITAL LP removed 816,326 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $10,661,217
• MILLENNIUM MANAGEMENT LLC added 704,762 shares (+84.8%) to their portfolio in Q1 2026, for an estimated $9,204,191
• POINT72 ASSET MANAGEMENT, L.P. removed 674,336 shares (-88.8%) from their portfolio in Q1 2026, for an estimated $8,806,828
• IKARIAN CAPITAL, LLC added 525,000 shares (+185.6%) to their portfolio in Q1 2026, for an estimated $6,856,500
• CITADEL ADVISORS LLC added 350,200 shares (+inf%) to their portfolio in Q1 2026, for an estimated $4,573,612
• LONGAEVA PARTNERS L.P. added 262,088 shares (+55.8%) to their portfolio in Q1 2026, for an estimated $3,422,869

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Read full article here »